Progress in molecular-based management of differentiated thyroid cancer

Mingzhao Xing, Bryan R. Haugen, Martin Schlumberger

Research output: Contribution to journalReview articlepeer-review

Abstract

Substantial developments have occurred in the past 5-10 years in clinical translational research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and BRAFV600E mutations; galectin 3; and a new gene expression classifier, are outstanding examples that have improved diagnosis of thyroid nodules. BRAF mutation is a prognostic genetic marker that has improved risk stratification and hence tailored management of patients with thyroid cancer, including those with conventionally low risks. Novel molecular-targeted treatments hold great promise for radioiodine-refractory and surgically inoperable thyroid cancers as shown in clinical trials; such treatments are likely to become a component of the standard treatment regimen for patients with thyroid cancer in the near future. These novel molecular-based management strategies for thyroid nodules and thyroid cancer are the most exciting developments in this unprecedented era of molecular thyroid-cancer medicine.

Original languageEnglish (US)
Pages (from-to)1058-1069
Number of pages12
JournalThe Lancet
Volume381
Issue number9871
DOIs
StatePublished - Mar 2013

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Progress in molecular-based management of differentiated thyroid cancer'. Together they form a unique fingerprint.

Cite this